• Home
  •  / Sarepta Therapeutics

Sarepta Therapeutics

OverviewSuggest Edit

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company's primary focus is on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy drug candidates.

TypePublic
Founded1980
HQCambridge, MA, USMap
Websitesarepta.com
Employee Ratings3.9More
View Jobs (147)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)743(+49%)
Job Openings147
Share Price (May 2022)$63.3
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sarepta Therapeutics

Douglas S. Ingram

Douglas S. Ingram

Chief Executive Officer and President
Diane Berry

Diane Berry

Vice President, Government Affairs and Global Health Policy
Louise Rodino-Klapac

Louise Rodino-Klapac

Executive Vice President, Head of Research and Development, Chief Scientific Officer
Ian M. Estepan

Ian M. Estepan

Executive Vice President, Chief Financial Officer
Gilmore O'Neill

Gilmore O'Neill

Executive Vice President, Research and Development and Chief Medical Officer
Show more

Sarepta Therapeutics Office Locations

Sarepta Therapeutics has offices in Cambridge, Canton, Providence, Boulogne-Billancourt and in 7 other locations
Cambridge, MA, US (HQ)
215 First St
Canton, MA, US
250 Royall St
Boulogne-Billancourt, FR
90 Route de la Reine
Berlin, DE
Friedrichstraße 88
Dublin, IE
Regus House, Harcourt Centre, Saint Kevin's
Milano, IT
Piazzale Biancamano, 8
Show all (12)

Sarepta Therapeutics Financials and Metrics

Sarepta Therapeutics Revenue

USD

Market capitalization (12-May-2022)

5.5b

Closing stock price (12-May-2022)

63.3

Cash (30-Jun-2021)

1.7b

EV

4.1b
Sarepta Therapeutics's current market capitalization is $5.5 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

39.9m187.7m257.0m73.6m80.3m122.4m599.7m370.8m835.1m1.5b

Accounts Receivable

3.6m4.7m3.5m2.4m4.0m5.2m29.5m49.0m90.9m101.3m

Prepaid Expenses

1.6m1.5m3.1m35.0m17.4m36.5m77.8m81.9m

Inventories

12.8m83.6m125.4m171.4m232.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

54.2m46.4m30.6m24.5m38.0m167.9m156.2m273.6m49.1m102.8m52.3m74.4m69.5m55.8m38.0m111.8m395.1m274.7m168.3m617.6m557.2m410.4m209.7m732.2m808.6m724.8m1.8b1.6b1.5b1.5b1.7b

Accounts Receivable

10.9m4.3m5.1m7.2m2.5m5.7m3.8m6.7m7.8m5.2m3.4m2.4m2.4m2.7m4.0m4.0m4.0m12.3m17.8m24.8m39.8m43.0m48.6m50.5m57.0m68.0m106.9m104.0m121.8m118.2m127.5m

Prepaid Expenses

943.0k1.3m1.9m1.6m1.7m3.0m5.7m2.8m9.1m15.9m26.4m24.4m23.1m19.5m16.9m15.3m22.0m22.7m28.6m27.0m31.2m43.0m54.8m136.2m110.8m79.0m

Inventories

2.9m30.4m41.8m64.7m99.4m104.1m115.8m140.5m156.6m166.4m173.2m179.7m220.1m240.3m268.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.3m)(121.3m)(112.0m)(135.8m)(220.0m)(267.3m)(50.7m)(361.9m)(715.1m)(554.1m)

Depreciation and Amortization

1.3m1.5m1.3m3.7m5.2m5.6m8.1m12.2m30.5m26.9m

Inventories

(12.8m)(70.8m)(41.8m)(45.9m)(60.6m)

Accounts Payable

9.5m10.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

3.1m(908.0k)(17.7m)(9.7m)(59.2m)(42.1m)(61.1m)(103.2m)(28.3m)(62.1m)(91.4m)(61.6m)(103.4m)(155.3m)(59.8m)(122.1m)(178.8m)84.1m21.0m(26.7m)(35.4m)(144.6m)(221.0m)(76.6m)(353.0m)(479.4m)(17.5m)(168.3m)(364.8m)(167.2m)(248.7m)

Depreciation and Amortization

490.0k763.0k353.0k715.0k1.1m451.0k711.0k998.0k523.0k1.5m2.5m1.3m2.6m3.9m1.4m2.9m3.9m1.6m3.4m6.0m2.3m5.1m8.7m6.4m14.1m22.3m6.5m13.0m19.6m8.9m17.4m

Inventories

(2.9m)(17.6m)(28.9m)(51.9m)(15.8m)(20.5m)(32.2m)(15.0m)(31.1m)(40.9m)(1.8m)(8.3m)(48.7m)(8.4m)(36.8m)

Accounts Payable

(294.0k)1.9m1.7m(4.3m)(4.5m)(5.1m)(566.0k)(3.1m)
show all
USDQ2, 2011

Financial Leverage

2.1 x
Show all financial metrics

Sarepta Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

Learn more about our premium products
SecurityScorecard logo

Sarepta Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Sarepta Therapeutics Online and Social Media Presence

Sarepta Therapeutics's Trends

Embed Graph

Sarepta Therapeutics News and Updates

May 04, 2022

Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11…
April 27, 2022

Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, May 4, 2022. Subsequently, at 4:30 p.m. E.…
March 08, 2022

Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the website for Route 79, The Duchenne Scholarship Program, is officially open and accepting applications. Academic schola…
March 01, 2022

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2021.
February 22, 2022

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022. Subsequently, a…
January 06, 2022

Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 1…
Show more

Sarepta Therapeutics Blogs

May 05, 2022

Sarepta Therapeutics Launches Inaugural LGMD Grant Award Program

Program website is now open and accepting applications through September 5, 2022 Up to $100,000 in total funds to be awarded to selected patient advocacy and non-governmental organizations CAMBRIDGE, Mass., May 5, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
May 04, 2022

Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments

Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8 million, a 51% increase over the same quarter of prior year CAMBRIDGE, Mass., May 04, 2022 (GLOBE
February 22, 2022

Sarepta Therapeutics Announces the Launch of SareptaCircle to Highlight the Experiences of Individuals and Families Living with Rare Disease

Sarepta Therapeutics Announces the Launch of SareptaCircle to Highlight the Experiences of Individuals and Families Living with Rare Disease Katherine.Howe… Tue, 02/22/2022 - 16:53 Sarepta Therapeutics Announces the Launch of SareptaCircle to Highlight the Experiences of Individuals and …
November 03, 2021

Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments

Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior year In light of its continued over-performance, Sarepta raises its full-year product revenue guidance by $40 million to between $605 million to $615 million CAMBRIDGE, Mass., Nov.
November 02, 2021

Sarepta Therapeutics at the Credit Suisse 30th Annual Healthcare Conference

Sarepta Therapeutics at the Credit Suisse 30th Annual Healthcare Conference Katherine.Howe… Tue, 11/02/2021 - 16:44 Sarepta Therapeutics at the Credit Suisse 30th Annual Healthcare Conference Display "add to calendar" true Event Type Other Co…
November 02, 2021

Sarepta Therapeutics at the Barclays Gene Editing & Gene Therapy Summit 2021

Sarepta Therapeutics at the Barclays Gene Editing & Gene Therapy Summit 2021 Katherine.Howe… Tue, 11/02/2021 - 16:44 Sarepta Therapeutics at the Barclays Gene Editing & Gene Therapy Summit 2021 Display "add to calendar" true Event Type …
Show more

 Sarepta Therapeutics Frequently Asked Questions

  • When was Sarepta Therapeutics founded?

    Sarepta Therapeutics was founded in 1980.

  • Who are Sarepta Therapeutics key executives?

    Sarepta Therapeutics's key executives are Douglas S. Ingram, Diane Berry and Louise Rodino-Klapac.

  • How many employees does Sarepta Therapeutics have?

    Sarepta Therapeutics has 743 employees.

  • Who are Sarepta Therapeutics competitors?

    Competitors of Sarepta Therapeutics include Lannett, Ionis Pharmaceuticals and Moderna.

  • Where is Sarepta Therapeutics headquarters?

    Sarepta Therapeutics headquarters is located at 215 First St, Cambridge.

  • Where are Sarepta Therapeutics offices?

    Sarepta Therapeutics has offices in Cambridge, Canton, Providence, Boulogne-Billancourt and in 7 other locations.

  • How many offices does Sarepta Therapeutics have?

    Sarepta Therapeutics has 12 offices.